Izumi Yamatani

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Klebsiella Pneumoniae

Genetic Diversity

Top Venues

Microbiology spectrum

This page only lists publications with an associated author ORCID identifier.

Publications

Izumi Yamatani, Akio Aono, Keiji Fujiwara, Takahiro Asami, Keisuke Kamada, Yuta Morishige, Yuriko Igarashi, Kinuyo Chikamatsu, Yoshiro Murase, Hiroyuki Yamada, Akiko Takaki, Kosaku Komiya, Satoshi Mitarai
In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates. Microbiology spectrum 12 (7) (2024)
Izumi Yamatani, Akio Aono, Keiji Fujiwara, Takahiro Asami, Keisuke Kamada, Yuta Morishige, Yuriko Igarashi, Kinuyo Chikamatsu, Yoshiro Murase, Hiroyuki Yamada, Akiko Takaki, Kosaku Komiya, Satoshi Mitarai
In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates. Microbiology spectrum 12 (7) (2024)
Izumi Yamatani, Akio Aono, Keiji Fujiwara, Takahiro Asami, Keisuke Kamada, Yuta Morishige, Yuriko Igarashi, Kinuyo Chikamatsu, Yoshiro Murase, Hiroyuki Yamada, Akiko Takaki, Kosaku Komiya, Satoshi Mitarai
In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates. Microbiology spectrum 12 (7) (2024)
Izumi Yamatani, Akio Aono, Keiji Fujiwara, Takahiro Asami, Keisuke Kamada, Yuta Morishige, Yuriko Igarashi, Kinuyo Chikamatsu, Yoshiro Murase, Hiroyuki Yamada, Akiko Takaki, Kosaku Komiya, Satoshi Mitarai
In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates. Microbiology spectrum (2024)